

**WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE  
CURRICULUM VITAE**

**NAME:** Laurence Bruce Givner, M.D.

**ADDRESS:**  
**BUSINESS:** Department of Pediatrics  
Wake Forest University School of Medicine  
Medical Center Boulevard  
Winston-Salem, North Carolina 27157  
Phone: (336) 716-6568  
Fax: (336) 716-7100  
E-mail: ---

**EDUCATION:**  
  
Temple University  
Philadelphia, Pennsylvania  
B.A.  
  
University of Maryland  
School of Medicine  
Baltimore, Maryland  
M.D.

**POSTDOCTORAL TRAINING:**  
  
University of Maryland Hospital  
Department of Pediatrics  
Baltimore, Maryland  
Resident  
University of Maryland Hospital  
Department of Pediatrics  
Chief Resident  
  
Baylor College of Medicine  
(Texas Children's Hospital, Ben Taub General Hospital,  
Jefferson Davis Hospital)  
Houston, Texas  
Fellowship, Pediatric Infectious Diseases

**EMPLOYMENT:**  
  
1984-1985 Instructor in Pediatrics  
Infectious Diseases Section  
Baylor College of Medicine  
Houston, Texas  
  
1985-1990 Assistant Professor of Pediatrics  
Infectious Diseases  
Bowman Gray School of Medicine  
of Wake Forest University  
Winston-Salem, North Carolina  
  
1990-1997 Associate Professor of Pediatrics  
Infectious Diseases

Bowman Gray School of Medicine  
of Wake Forest University

1996-	Chief, Pediatric Infectious Diseases Wake Forest University School of Medicine (formerly, Bowman Gray School of Medicine of Wake Forest University)
1996-	Medical Director, Pediatric Inpatient Units Brenner Children's Hospital Winston-Salem, North Carolina
1997-	Professor of Pediatrics (with tenure) Infectious Diseases Wake Forest University School of Medicine
1999-	Vice Chair for Clinical Affairs Department of Pediatrics Wake Forest University School of Medicine

**PROFESSIONAL LICENSURE:**

Maryland State Board of Medical Examiners (inactive)

Texas State Board of Medical Examiners (inactive)

North Carolina State Board of Medical Examiners

**SPECIALTY CERTIFICATION:**

American Board of Pediatrics  
General Pediatrics  
Pediatric Infectious Diseases  
Pediatric Infectious Diseases, Recertification

**PROFESSIONAL MEMBERSHIPS:**

1985	North Carolina Pediatric Society
1986	Fellow, American Academy of Pediatrics
1988	Fellow, Pediatric Infectious Diseases Society
1991	Society for Pediatric Research
1992	Fellow, Infectious Diseases Society of America
1997	American Pediatric Society

**OTHER PROFESSIONAL APPOINTMENTS AND ACTIVITIES:**

**Intramural:**

**Department of Pediatrics**

**Wake Forest University School of Medicine:**

1986-1990	Housestaff Selection Committee
1996-	Student Education Committee
1996-	Faculty Advisory Committee
1997-	Faculty Promotions Committee
1997-	Faculty and Housestaff Committee
1998-	Information Services/Computer Committee
1999-	Faculty Tenure Committee

**Wake Forest University School of Medicine:**

1987-1993	Biosafety Committee
1990-1993	Associate Dean's Advisory Committee
1992-1995	Intramural Research Support Committee
1996-1998	Student Promotions Committee
1998-2000	Graduate Medical Education Committee
1998-	Biosafety Committee
1999	Liaison Committee on Medical Education Self-Study Task Force Subcommittee on Graduate Medical Education/Continuing Medical Education
2000-	Chair Committee on Ethics in Research
2001	Search Committee for New Dean

**North Carolina Baptist Hospital:**

1987-	Infection Control Committee
1997-1998	Intravenous Immunoglobulin Subcommittee Pharmacy and Therapeutics Committee
2002-2003	Search Committee Medical Director, Clinical Microbiology Lab

**Brenner Children's Hospital:**

1996-	Chair Pediatric Inpatient Units Committee
-------	--

1997- Pediatric Facilities and Programs Executive Committee

1997- Chair  
Inpatient Facilities and Programs Committee

1998- Emergency Department Advisory Committee

**Wake Forest University Physicians:**

1997- Business Operations Committee

2001- Contracting Subcommittee  
WFUP Executive Committee

**Wake Forest University Baptist Medical Center:**

1999 Strategic Planning Work Group

2000- Center for Antimicrobial Utilization, Stewardship  
and Epidemiology (CAUSE)

2002- Board of Trustees  
The Medical Foundation

2002- Steering Committee  
Brenner Children's Health Services

2002- Smallpox Readiness Task Force

**Amos Cottage Rehabilitative Hospital:**

1999-2002 Executive Committee

**Extramural:**

**National Institute of Child Health and Human Development:**

January 9, 1990 Ad Hoc Grant Review Committee

August 7, 1990 Ad Hoc Grant Review Committee

**Food and Drug Administration:**

2002-2007 Microbiology Devices Advisory Panel

**Society for Pediatric Research:**

May 5, 1994 Moderator  
Neonatal Infectious Diseases Platform Session  
Annual Meeting  
Seattle, Washington

May 4, 1998 Moderator  
Infectious Diseases Platform Session  
Annual Meeting  
New Orleans, Louisiana

2002- Annual Meeting Program Committee

**Pediatric Infectious Diseases Society:**

2000- Communications Committee

2002- Council (Elected Member)

2002- Chair  
Programs and Meetings Committee

**Infectious Diseases Society of America:**

2002- Annual Meeting Program Committee

**Industry:**

October 17, 1991 Special Advisory Panel  
Johnson and Johnson Pharmaceuticals  
Raritan, New Jersey  
"Hyperimmune Antibody Products"

May 6-7, 1994 Special Advisory Panel  
Baxter Hyland Healthcare Corp.  
Scottsdale, Arizona  
"The Future of IVIG"

September 21, 1994 Special Advisory Panel  
University Hospital Consortium  
Chicago, Illinois  
"Non-Label Uses of IVIG"

July 28, 1995 Special Advisory Panel  
MedImmune, Inc.  
Gaithersburg, Maryland  
"Monoclonal Antibodies Against RSV: Future Directions"

December 15, 1995 Consultant for MedImmune, Inc.  
Blood Products Advisory Committee Meeting  
Food and Drug Administration  
Rockville, Maryland  
"Licensure of RSV-IVIG (RespiGam)"

September 21-23, 1997 Special Advisory Panel  
Baxter Healthcare  
Sonoma, California  
"Hyperimmune Antibody Products"

January 15-17, 1999 Special Advisory Board  
Bayer Pharmaceuticals  
Miami Beach, Florida  
"Hyperimmune Products"

January 11-13, 2001	Special Advisory Panel Pfizer Pharmaceuticals Dallas, Texas "Zithromax and Pediatrics"
2001-	Data Safety Monitoring Board Biosynexus, Inc Gaithersburg, Maryland "Anti-Staphylococcal Monoclonal Antibody"
2001-	Advisory Board ProLacta BioScience Temecula, California
2002-	Expert Panel Inhibitex, Inc Atlanta, Georgia "Polyclonal Anti-Staphylococcal Human Immune Globulin"

#### HONORS AND AWARDS:

	Phi Beta Kappa, Temple University
	President's Scholar, Temple University
1980-1981	Abraham H. Finkelstein Award for Teaching Excellence Department of Pediatrics University of Maryland Hospital
1998, 2000, 2001-2	Best Doctors in America Woodward/White
2000	Jimmy L. Simon, MD Excellence in Teaching Award Department of Pediatrics Wake Forest University School of Medicine
2001, 2002	America's Top Doctors Castle Connolly Medical Ltd
2002	Teaching Excellence Award Wake Forest University School of Medicine

#### LECTURES, SPEECHES, EXHIBITS, FILMS:

"Antimicrobial Therapy for Skin Infections and Animal Bites," Grand Rounds, Department of Pediatrics, Children's Hospital, Greenville, South Carolina, September 30, 1988.

"Immunoprophylaxis and Immunotherapy of Neonatal Sepsis." Grand Rounds, Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh,

Pennsylvania, November 2, 1989.

"Immunoprophylaxis and Immunotherapy of Neonatal Sepsis," Infectious Diseases Lecture, Duke University School of Medicine, Durham, North Carolina, January 29, 1990.

"Immunoprophylaxis and Immunotherapy of Neonatal Sepsis," Grand Rounds, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, June 8, 1990.

"Immunoprophylaxis and Immunotherapy of Neonatal Sepsis," Neonatology Lecture, East Carolina University School of Medicine, Greenville, North Carolina, June 27, 1991.

"Group B Streptococcal Infections in Newborns: An Overview," Presented to the Annual Meeting of the Spanish Pediatric Society, Mallorca, Spain, December 5, 1991.

"Toxic Shock and the Return of Group A Streptococcal Infections," "Neonatal Sepsis in the Era of Maternal Intrapartum Chemoprophylaxis," Postgraduate Course, Department of Pediatrics, Henrico Doctors' Hospital, Richmond, Virginia, October 15, 1993.

"Prevention of Infection in Low-Birth-Weight Neonates with IVIG," Presented at the European Symposium on Intravenous Immunoglobulins: Current Status of Clinical Applications and Research Topics, Lisbon, Portugal, November 8, 1993.

"Chemoprophylaxis for the Prevention of Perinatal Group B Streptococcal Infections," Presented at Perinatal Infections in the 1990s, A Symposium, University of North Carolina, Chapel Hill, North Carolina, March 3, 1994.

"Current Issues in Neonatal Group B Streptococcal Infections," Obstetric/Gynecologic and Pediatric Physician Symposium, Sinai Hospital of Baltimore, Baltimore, Maryland, November 18, 1994.

"Group B Strep: Diagnosis and Management," American College of Obstetricians and Gynecologists Update program audiotape, Vol 20 (No 12), 1995.

"Group A Strep," Infectious Diseases Update, Department of Pediatrics, Arkansas Children's Hospital, University of Arkansas School of Medicine, Little Rock, Arkansas, March 11, 1995.

"The Case for Chemoprophylaxis of Group B Streptococcal Disease," Meeting of the Hospital Infection Society, London, England, April 7, 1995.

Moderator of The Management of RSV Conference, Charlotte, North Carolina, July 19-20, 1996.

"Respiratory Syncytial Virus: Overview and Prevention," Presented at the Annual Meeting of the South Carolina Chapter of the American Academy of Pediatrics, Myrtle Beach, South Carolina, August 8, 1996

"RSV Disease and Its Prevention," Grand Rounds, Department of Pediatrics, Children's Hospital, University of Alabama School of Medicine at Birmingham, Birmingham, Alabama, October 10, 1996.

"Worldwide Impact of Perinatal Group B Streptococcal Infections," Presented to the First World Congress on Pediatric Infectious Diseases, Acapulco, Mexico, December 7, 1996.

"Maternal Intrapartum Chemoprophylaxis: New Recommendations and Approach to the Newborn Infant,"  
"Respiratory Syncytial Virus Infections," "Invasive Disease due to Group A Streptococcus," "Pediatric Infectious Diseases Seminar, Lake Buena Vista, Florida, October 15-18, 1997.

"Respiratory Syncytial Virus: New Preventive Methods," Grand Rounds, Department of Pediatrics, East Carolina University School of Medicine, Greenville, North Carolina, February 6, 1998.

"Rocky Mountain Spotted Fever," Annual Meeting of the American Academy of Pediatrics, Atlanta, Georgia, April 7, 1998.

"Antibiotic Resistance," Annual Meeting of the American Academy of Pediatrics, Boston, Massachusetts, October 19-23, 2002.

"Infectious Diseases Cases," Annual Meeting of the American Academy of Pediatrics, Boston, Massachusetts, October 19-23, 2002.

"Pediatric Bone and Joint Infections- Meet the Professor," Annual Meeting of the Infectious Diseases Society of America, Chicago, Illinois, October 24-27, 2002.

#### **EDITORSHIPS:**

##### **Guest Editor:**

April & July 1999 Issues

Seminars in Pediatric Infectious Diseases  
"Infectious Diseases in the Newborn Infant"  
Givner, LB

January 2001 Issue

Seminars in Pediatric Infectious Diseases  
"Adjunctive Therapies for Treatment  
or Prevention of Sepsis"  
Weisman LE, Givner LB

##### **Editorial Boards:**

1997-

Concise Reviews in Pediatric Infectious Diseases  
(formerly Report on Pediatric Infectious Diseases)

1997 -

Seminars in Pediatric Infectious Diseases

#### **BIBLIOGRAPHY:**

##### **Monographs:**

1. Ratko TA for the University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations (**Givner LB**, member of expert panel). Technology assessment: Intravenous immunoglobulin preparations. Oak Brook, IL: UHC, 1995.
2. Ratko TA for the University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations (**Givner LB**, member of expert panel). Technology assessment: Intravenous immunoglobulin preparations. Oak Brook, IL: UHC, 1999.

##### **Chapters in Books:**

1. **Givner LB**, Anderson DC. Active immunizing agents. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases, 2nd ed. Philadelphia: W.B. Saunders, 1987:2263-2294.
2. **Givner LB**. Anthrax. In: Nelson JD, ed. Current therapy in pediatric infectious disease, 2nd ed. Philadelphia: B.C. Decker, 1988:185-186.



3. Anderson DC, **Givner LB**, Shearer WT. Active and passive immunization in the prevention of infectious diseases. In: Stiehm ER, ed. Immunologic disorders in infants and children, 3rd ed. Philadelphia: W.B. Saunders, 1989:689-728.
4. **Givner LB**. Enteroviruses. In: Burg FD, Ingelfinger JR, Wald ER, eds. Gellis and Kagan's current pediatric therapy, 14th ed. Philadelphia: W.B. Saunders, 1993:619-620.
5. **Givner LB**. Anthrax. In: Kaplan SL, ed. Current therapy in pediatric infectious disease, 3rd ed. Philadelphia: B.C. Decker, 1993:184-185.
6. Abramson JS, **Givner LB**. Rickettsial diseases. In: Kaplan SL, ed. Current therapy in pediatric infectious disease, 3rd ed. Philadelphia: B.C. Decker, 1993:241-243.
7. **Givner LB**. Aseptic meningitis. In: Burg FD, Ingelfinger JR, Wald ER, Polin RA, eds. Gellis and Kagan's current pediatric therapy, 15th ed. Philadelphia: W.B. Saunders, 1996:637.
8. **Givner LB**. Group A Streptococcal infections. In: Sherertz R, Streed S, Gledhill K, eds. The practice of infection control. (In press)
9. **Givner LB**. Group B Streptococcal infections. In: Sherertz R, Streed S, Gledhill K, eds. The practice of infection control. (In press)

#### **Journal Articles:**

1. **Givner LB**, Rennels MB, Woodward CL, Huang S-W. Chlamydia trachomatis infection in an infant delivered by cesarean section. Pediatrics 1981;68:420-421.
2. **Givner LB**, Luddy RE, Schwartz AD. Etiology of osteomyelitis in patients with major sickle hemoglobinopathies. J Pediatr 1981;99:411-413.
3. Ringel RE, **Givner LB**, Brenner JI, Huang S-W, Wang S-P, Grayston JT, Berman MA. Myocarditis as a complication of infantile Chlamydia trachomatis pneumonitis. Clin Pediatr 1983;22:631-633.
4. **Givner LB**, Baker CJ. Anaerobic meningitis associated with a dermal sinus tract. Pediatr Infect Dis 1983;2:385-387.
5. Bush JK, **Givner LB**, Whitaker SH, Anderson DC, Percy AK. Necrotizing fasciitis of the parapharyngeal space with carotid artery occlusion and acute hemiplegia. Pediatrics 1984;73:343-347.
6. **Givner LB**, McGehee D, Taber LH, Stein F, Sumaya CV. Sinusitis, orbital cellulitis and polymicrobial bacteremia in a patient with primary Epstein-Barr virus infection. Pediatr Infect Dis 1984;3:254-256.
7. **Givner LB**, Edwards MS, Anderson DC, Baker CJ. Immune globulin for intravenous use: enhancement of in vitro opsonophagocytic activity of neonatal serum. J Infect Dis 1985;151:217-220.
8. **Givner LB**, Baker CJ, Edwards MS. Type III group B Streptococcus: functional interaction with IgG subclass antibodies. J Infect Dis 1987;155:532-539.

9. **Givner LB**, Edwards MS, Baker CJ. A polyclonal human IgG preparation hyperimmune for type III, group B Streptococcus: in vitro opsonophagocytic activity and efficacy in experimental models. J Infect Dis 1988;158:724-730.
10. **Givner LB**, Baker CJ. The prevention and treatment of neonatal group B streptococcal infections. Adv Pediatr Infect Dis 1988;3:65-90.
11. Abramson JS, **Givner LB**, Thompson JN. The possible role of tonsillectomy and adenoidectomy in children with recurrent fever and tonsillopharyngitis. Pediatr Infect Dis J 1989;8:119-120.
12. **Givner LB**, Abramson JS, Wasilauskas B. Meningitis due to Haemophilus influenzae type b resistant to ampicillin and chloramphenicol. Rev Infect Dis 1989;11:329-334.
13. Abramson JS, **Givner LB**. Should tetracycline be contraindicated for therapy of presumed Rocky Mountain spotted fever in children less than nine years of age? Pediatrics 1990;86:123-124. (Editorial)
14. **Givner LB**. Therapy of acute pyelonephritis- from hospital to home. Semin Pediatr Infect Dis 1990;1:349-362.
15. **Givner LB**. Human immune globulins for intravenous use: comparison of available preparations for group B Streptococcal antibody levels, opsonic activity and efficacy in animal models. Pediatrics 1990;86:955-962. [Published with accompanying Commentary: Baker CJ, Edwards MS. Evaluating the protective activity of intravenous immunoglobulins for neonatal pathogens. Pediatrics 1990;86:995-997]
16. Ernest JM, **Givner LB**, Pool R. Intrapartum hepatitis B screening in a low risk population. Am J Obstet Gyn 1990;163:978-980.
17. **Givner LB**, Abramson JS, Wasilauskas B. Apparent increase in the incidence of invasive group A beta-hemolytic streptococcal disease in children. J Pediatr 1991;118:341-346. [Cited in The Year Book of Infectious Diseases, 1993, pp.20-23]
18. **Givner LB**. Group B streptococcal infections in newborns. Anales Espanoles de Pediatria 1991;35:126-128.
19. Sherertz RJ, Gledhill KS, Hampton KD, Pfaller MA, **Givner LB**, Abramson JS, Dillard RG. Outbreak of Candida bloodstream infections in a neonatal intensive care unit associated with retrograde medication administration. J Pediatr 1992;120:455-461.
20. **Givner LB**, Baker CJ. Pooled human IgG hyperimmune for type III group B Streptococcus: evaluation against multiple strains in vitro and in experimental disease. J Infect Dis 1991;163:1141-1145.
21. Wheeler JG, **Givner LB**. Therapeutic use of recombinant human granulocyte/macrophage colony-stimulating factor in neonatal rats with type III group B streptococcal sepsis. J Infect Dis 1992; 165:938-941.
22. Baker CJ, Melish ME, Hall RT, Casto DT, Vasan U, **Givner LB**, and the Multicenter Group for the Study of Immune Globulin in Neonates. Intravenous immune globulin for the prevention of nosocomial infection in low birth weight neonates. N Engl J Med 1992;327:213-219.

23. **Givner LB**, Kaplan SL. Meningitis due to Staphylococcus aureus in children. Clin Infect Dis 1993; 16:766-771.
24. **Givner LB**, Nagaraj SK. Hyperimmune human IgG or recombinant human granulocyte-macrophage colony-stimulating factor for adjunctive therapy of group B Streptococcal sepsis in newborn rats. J Pediatr 1993;122:774-779.
25. Abramson JS, **Givner LB**. Rocky Mountain spotted fever. Semin Pediatr Infect Dis 1994;5:131-136.
26. Ernest JM, **Givner LB**. A prospective, randomized, placebo-controlled trial of penicillin in preterm-PROM. Am J Ob Gyn 1994;170:516-521.
27. **Givner LB**, Woods CR Jr, Abramson JS. The practice of pediatrics in the era of vaccines effective against Haemophilus influenzae type b. Pediatrics 1994;93:680-681. (Editorial)
28. Woods CR Jr, Smith AL, Wasilaukas BL, Campos J, **Givner LB**. Invasive disease caused by Neisseria meningitidis relatively resistant to penicillin in North Carolina. J Infect Dis 1994;170:453-456.
29. Istas AS, Demmler GJ, Dobbins JG, Stewart JA, and the National Congenital Cytomegalovirus Disease Registry Collaborating Group (**Givner LB**, Principal Investigator at Bowman Gray). Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995;20:665-670.
30. Horn CA, Washburn RG, **Givner LB**, Peacock JE Jr, Pegram PS. Azole-resistant oropharyngeal and esophageal candidiasis in patients with AIDS. AIDS 1995;9:533-535.
31. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA, and the University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations (**Givner LB**, member of expert panel). Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995;273:1865-1870.
32. Ford JG, Yeatts RP, **Givner LB**. Orbital cellulitis, subperiosteal abscess, sinusitis and septicemia caused by Arcanobacterium haemolyticum. Am J Ophthalmol 1995;120:261-262.
33. **Givner LB**, Gray L, O'Shea TM. Antibodies to tumor necrosis factor-alpha: use as adjunctive therapy in established group B streptococcal disease in newborn rats. Pediatr Res 1995;38:551-554. [Cited in The Year Book of Neonatal and Perinatal Medicine, 1996, pp.129-131]
34. **Givner LB**. Management of newborn infants whose mothers received intrapartum antimicrobial chemoprophylaxis. Rep Pediatr Infect Dis 1996;6:33-34.
35. Woods CR Jr, **Givner LB**. Drug-resistant meningococcal infections. Semin Pediatr Infect Dis 1996; 7:204-211.
36. The PREVENT Study Group (**Givner LB**, Principal Investigator at Bowman Gray). Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using Respiratory Syncytial Virus Immune Globulin prophylaxis. Pediatrics 1997;99:93-99.
37. **Givner LB**. Invasive disease due to group A beta-hemolytic streptococci: Continued occurrence in children in North Carolina. South Med J 1998;91:333-337.

38. Siva Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez J, Steichen J, **Givner LB**, Jennings TL, Top FH Jr, Carlin D and Connor E for the MEDI-493 Study Group. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. *Pediatr Infect Dis J* 1998;17:110-115.
39. O'Shea TM, Sevick MA, **Givner LB**. Costs and benefits of respiratory syncytial virus immune globulin to prevent hospitalization due to lower respiratory tract illness in very low birth weight infants. *Pediatr Infect Dis J* 1998;17:587-593.
40. Kaplan SL, Mason EO Jr, Barson WJ, Wald ER, Arditi M, Tan TQ, Schutze GE, Bradley JS, **Givner LB**, Kim KS, Yogev R. Three year multicenter surveillance of systemic pneumococcal infections in children. *Pediatrics* 1998;102:538-545.
41. The IMpact-RSV Study Group (**Givner LB**, Principal Investigator at Wake Forest). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high risk infants. *Pediatrics* 1998;102:531-537.
42. Arditi M, Mason EO Jr, Bradley JS, Tan TQ, Barson WJ, Schutze GE, Wald ER, **Givner LB**, Kim KS, Yogev R, Kaplan SL. Three year multicenter surveillance of pneumococcal meningitis in children: Clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. *Pediatrics* 1998; 102:1087-1097.
43. Tan TQ, Mason EO Jr, Barson WJ, Wald ER, Schutze GE, Bradley JS, Arditi M, **Givner LB**, Yogev R, Kim KS, Kaplan SL. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible *Streptococcus pneumoniae*. *Pediatrics* 1998;102:1369-1375.
44. Bradley JS, Kaplan SL, Tan TQ, Barson WJ, Arditi M, Schutze GE, Wald ER, **Givner LB**, Mason EO, and the Pediatric Multicenter Pneumococcal Surveillance Study Group. Pediatric pneumococcal bone and joint infections. *Pediatrics* 1998;102:1376-1382.
45. Abramson JS, **Givner LB**. Bacterial resistance due to antimicrobial drug addiction among physicians – time for a cure. *Arch Fam Med* 1999;8:79-80. (Editorial)
46. Cairo MS, Agosti J, Ellis R, Laver JJ, Puppala B, deLemos R, **Givner LB**, Nesin M, Wheeler JG, Seth T, van de Ven C, Fanaroff A, and the Very Low Birthweight Neonate GM-CSF Consortium. A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates. *J Pediatr* 1999;134:64-70.
47. Abramson JS, **Givner LB**. Rocky Mountain spotted fever. *Pediatr Infect Dis J* 1999;18:539-540.
48. **Givner LB**. Monoclonal antibodies against respiratory syncytial virus. *Pediatr Infect Dis J* 1999;18:541-542.
49. Bitzan MM, Nagaraj SK, Georgitis JW, **Givner LB**, Lorentz WB, Iskandar SS. *Staphylococcus aureus* pneumonia, hyponatremia, hypertension, proteinuria and hematuria in a 14-year-old boy. *Am J Kidney Dis* 2000;35:354-359.

50. Kaplan SL, Mason EO Jr, Wald ER, Kim KS, **Givner LB**, Bradley JS, Barson WJ, Tan TQ, Schutze GE, Yogev R. Pneumococcal mastoiditis in children. *Pediatrics* 2000;106:695-699.
51. **Givner LB**, Mason EO Jr, Barson WJ, Tan TQ, Wald ER, Schutze GE, Kim KS, Bradley JS, Yogev R, Kaplan SL. Pneumococcal facial cellulitis in children. *Pediatrics* 2000;106:e61,pp1-4.
52. Kaplan SL, Mason EO Jr, Barson WJ, Tan TQ, Schutze GE, Bradley JS, **Givner LB**, Kim KS, Yogev R, Wald ER. Outcome of invasive infections outside the central nervous system caused by *Streptococcus pneumoniae* isolates non-susceptible to ceftriaxone in children treated with  $\beta$ -lactam antibiotics. *Pediatr Infect Dis J* 2001;20:392-396.
53. Schutze GE, Mason EO Jr, Wald ER, Barson WJ, Bradley JS, Tan TQ, Kim KS, **Givner LB**, Yogev R, Kaplan SL. Pneumococcal infections in children after transplantation. *Clin Infect Dis* 2001;33:16-21.
54. Orlicek SL, Abramson JS, Woods CR, **Givner LB**. Obturator internus muscle abscess in children. *J Pediatr Orthopaedics* 2001;21:744-748.
55. Kaplan SL, Mason EO Jr, Wald ER, Tan TQ, Schutze GE, Bradley JS, **Givner LB**, Kim KS, Yogev R, Barson WJ. Six-year multicenter surveillance of invasive pneumococcal infections in children. *Pediatr Infect Dis J* 2002;21:141-147.
56. Schutze GE, Mason EO Jr, Barson WJ, Kim KS, Wald ER, **Givner LB**, Tan TQ, Bradley JS, Yogev R, Kaplan SL. Invasive pneumococcal infections in children with asplenia. *Pediatr Infect Dis J* 2002;21:278-82.
57. Tan TQ, Mason EO Jr, Wald ER, Barson WJ, Schutze GE, Bradley JS, **Givner LB**, Yogev R, Kim KS, Kaplan SL. Clinical characteristics of children with complicated pneumonia caused by *Streptococcus pneumoniae*. *Pediatrics* 2002;110:1-6.
58. Shetty AK, Beaty MW, McGuirt WF Jr, Woods CR, **Givner LB**. Kimura's disease: A diagnostic challenge. *Pediatrics* 2002;110:e39,pp1-4.
59. **Givner LB**. Periorbital and orbital cellulitis. *Pediatr Infect Dis J* 2002;21:1157-8.
60. Hoffman JA, Mason EO, Schutze GE, Tan TQ, Barson WJ, **Givner LB**, Wald ER, Bradley JS, Yogev R, Kaplan SL. *Streptococcus pneumoniae* infections in neonates. *Pediatrics*, in press.

#### **Abstracts:**

1. **Givner LB**, Edwards MS, Baker CJ, Anderson DC. Opsonic activity of neonatal sera for type III, group B *Streptococcus* with addition of modified immune serum globulin in vitro. Presented to the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, Nevada, October 24, 1983.
2. **Givner LB**, Edwards MS, Baker CJ. Distribution and functional activity of human IgG subclass-specific antibodies to native type III group B streptococcal polysaccharide. *Pediatr Res* 1985; 19:294A.
3. **Givner LB**, Baker CJ, Edwards MS. In vitro efficacy of a human hyperimmune globulin for type III, group B streptococci. Presented to the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Minneapolis, Minnesota, September 30, 1985.

4. **Givner LB.** Protective efficacy of a hyperimmune human IgG preparation in experimental type III group B streptococcal infection. Presented to the Lancefield Society, New Orleans, Louisiana, October 1, 1986.
5. **Givner LB.** Human IgG hyperimmune for type III group B Streptococcus: efficacy in newborn rats. Presented to the Society for Pediatric Research, Washington, DC, May 4, 1988.
6. **Givner LB.** Human immune globulins for intravenous use: comparison of available preparations in experimental group B streptococcal disease. Presented to the Lancefield Society, Los Angeles, California, October 26, 1988.
7. **Givner LB.** Human immunoglobulins for intravenous use: comparison of available preparations for activity against group B Streptococcus. Presented to the Society for Pediatric Research, Washington, DC, May 4, 1989.
8. Baker CJ. The Multicenter Group for the Study of IVIG in Neonates (**Givner LB**: Principal Investigator at Bowman Gray). Multicenter trial of intravenous immunoglobulin to prevent late-onset infection in preterm infants: Preliminary results. Presented to the Society for Pediatric Research, Washington, DC, May 4, 1989.
9. Ernest JM, **Givner LB**, Poole R. Intrapartum hepatitis B screening in a low risk population. Presented to the Society of Perinatal Obstetricians, Houston, Texas, January 27, 1990.
10. Wheeler JG, **Givner LB.** Recombinant granulocyte-macrophage colony stimulating factor reduces mortality in neonatal rats infected with III-Group B Streptococcus. Presented to the American Society for Biochemistry and Molecular Biology, New Orleans, Louisiana, June 3-7, 1990.
11. Sherertz RJ, Hampton KD, Gledhill LK, Abramson JS, **Givner LB**, Dillard RG. An outbreak of candidemia associated with retrograde medication administration in a neonatal intensive care unit. Presented to the Third International Conference on Nosocomial Infections, Atlanta, Georgia, July 31-August 3, 1990.
12. Faircloth WB, Bell WO, Abramson JS, **Givner LB.** Loculated subarachnoid pus: a complication of childhood bacterial meningitis. Presented to the American Association of Neurological Surgeons, San Diego, California, December 7, 1990.
13. **Givner LB**, Baker CJ. Multi-donor pooled human IgG hyperimmune for type III group B Streptococcus. Presented to the Society for Pediatric Research, New Orleans, Louisiana, April 29, 1991.
14. Abramson JS, Sherertz RJ, Hampton KD, Gledhill LK, **Givner LB**, Dillard RG. Outbreak of candidemia due to retrograde medication administration in a neonatal intensive care unit. Presented to the Society for Pediatric Research, New Orleans, Louisiana, April 29, 1991.
15. Wheeler JG, **Givner LB.** The effect and mechanism of action of granulocyte/macrophage colony-stimulating factor on mortality in group B Streptococcus septic neonatal rats. Presented to the Society for Pediatric Research, New Orleans, Louisiana, April 29, 1991.
16. Ernest JM, **Givner LB**, Swain M, Henderson L. Penicillin reduces intra-amniotic infection in preterm PROM. Presented to the Infectious Diseases Society for Obstetrics and Gynecology, Bermuda, August

1-3, 1991.

17. Ernest JM, **Givner LB**, Swain M. Penicillin prophylaxis in preterm-premature rupture of the fetal membranes. Presented to the International Conference on the Prevention of Infection, Nice, France, May 4, 1992.
18. Nagaraj SK, Hudspeth S, Baker CJ, **Givner LB**. Human IgG hyperimmune for type III group B streptococcus: synergistic effect with penicillin in treatment of sepsis in suckling rats. Presented to the Society for Pediatric Research, Baltimore, Maryland, May 6, 1992.
19. **Givner LB**, Kaplan SL. Meningitis due to Staphylococcus aureus in children. Presented to the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October 14, 1992.
20. Woods CR, Wasilauskas B, **Givner LB**. Meningitis caused by Neisseria meningitidis relatively resistant to penicillin in North Carolina. Presented to the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October 14, 1992.
21. **Givner LB**, Nagaraj SK. Recombinant human granulocyte-macrophage colony-stimulating factor for adjunctive therapy of group B Streptococcal sepsis in newborn rats. Presented to the Society for Pediatric Research, Washington, DC, May 4, 1993.
22. Demmler GJ, Ista AS, Dobbins JG, Stewart JA, and the National Congenital CMV Disease Registry Collaborating Group. Surveillance of symptomatic congenital cytomegalovirus disease. *Pediatr Res* 1994; 35:112A.
23. Horn CA, Washburn RG, **Givner LB**, Peacock JE Jr, Pegram PS. Azole-resistant, progressive oropharyngeal and esophageal candidiasis in patients with AIDS: a re-emerging indication for Amphotericin B. Presented to 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 7, 1994.
24. **Givner LB**, Gray L, O'Shea TM. Antibodies to tumor necrosis factor-alpha for adjunctive therapy in experimental group B Streptococcal sepsis. Presented to the Society for Pediatric Research, San Diego, California, May 9, 1995.
25. Kaplan SL and the U.S. Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Bowman Gray). One-year surveillance of systemic pneumococcal infections in children. Presented to the Society for Pediatric Research, San Diego, California, May 9, 1995.
26. **Givner LB**. Invasive disease due to group A beta-hemolytic Streptococci in children in North Carolina. Presented to the Lancefield Society, San Francisco, California, September 17, 1995.
27. Connor EM for the PREVENT Study Group (**Givner LB**, Principal Investigator at Bowman Gray). Reduction of respiratory syncytial virus-associated hospitalization in children with premature birth and/or bronchopulmonary dysplasia using monthly infusions of RSV immune globulin. Presented to the Society for Pediatric Research, Washington, DC, May 7, 1996.
28. Tan TQ and the US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Bowman Gray). Clinical characteristics of children with pneumococcal pneumonia. Presented to the Society for Pediatric Research, Washington, DC, May 10, 1996.

29. Cairo MS, Seth T, Fanaroff A, Puppala B, DeLemos R, **Givner LB**, Laver J, Nesin M, Wheeler G, Agosti A. A double-blinded, randomized, placebo-controlled pilot study of RhGM-CSF in low birth weight neonates. Preliminary results demonstrate a significant reduction in nosocomial infections with RhGM-CSF. Presented to the Society for Pediatric Research, Washington, DC, May 10, 1996.
30. **Givner LB**. Continued occurrence of invasive disease due to group A beta-hemolytic streptococci in children in North Carolina. *Pediatr Res* 1996; 39:172A.
31. Kaplan SL and The US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Bowman Gray). Surveillance of pneumococcal infections in children. Presented to the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 16, 1996.
32. Arditi M and The US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Bowman Gray). Clinical and microbiological characteristics of pneumococcal meningitis in children. Presented to the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 16, 1996.
33. O'Shea TM, Sevick MA, **Givner LB**. Cost and benefits of prophylaxis of very low birth weight infants with Respiratory Syncytial Virus Immune Globulin. Presented to the Society for Pediatric Research, Washington, DC, May 5, 1997.
34. **Givner LB**. Invasive disease due to group A beta-hemolytic streptococci continues to occur in children in North Carolina. *Pediatr Res* 1997; 41:120A.
35. Siva Subramanian KN, Weisman L, Rhodes T, Connor E and the MEDI-493 Study Group (**Givner LB**, Principal Investigator at Bowman Gray). Randomized, double-blind, placebo-controlled, dose-escalation trial of a humanized respiratory syncytial virus monoclonal antibody (MEDI-493) in high risk infants. Presented to the Society for Pediatric Research, Washington DC, May 6, 1997.
36. Connor EM for the Impact-RSV Study Group (**Givner LB**, Principal Investigator at Wake Forest). Reduction of respiratory syncytial virus (RSV) hospitalization in children with prematurity or bronchopulmonary dysplasia using intramuscular humanized monoclonal antibody to the RSV F-protein (MEDI-493, palivizumab). Presented to the Society for Pediatric Research, New Orleans, Louisiana, May 4, 1998.
37. Mason EO Jr and the US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Wake Forest). Recurrent systemic pneumococcal disease in children. Presented to the First International Symposium on Pneumococci and Pneumococcal Diseases. Elsinore, Denmark, June 13-17, 1998.
38. Tan TQ, Mason EO, Barson WJ, Wald ER, Schutze GE, Bradley JS, Arditi M, **Givner LB**, Yogev R, Kaplan SL. Clinical characteristics of children with complicated pneumococcal pneumonia. Presented to the Society for Pediatric Research, San Francisco, California, May 4, 1999.
39. Null DM Jr, Connor EM, Palivizumab Study Group (**Givner LB**, Principal Investigator at Wake Forest). Evaluation of immunogenicity and safety in children receiving palivizumab for a second RSV season. Presented to the Society for Pediatric Research, San Francisco, California, May 4, 1999.



40. Kaplan SL and the US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Wake Forest). Pneumococcal mastoiditis in children. Presented to the Society for Pediatric Research, San Francisco, California, May 4, 1999.
41. Jones DS, Loyd J, Glazier SS, Opatowsky MJ, **Givner LB**. Chronic Group B Streptococcal ventriculitis. Presented to the Pediatric Neurosurgical Society, Atlanta, Georgia, December 1, 1999.
42. Tan TQ, Mason EO Jr, Barson WJ, Wald ER, Schutze GE, Bradley JS, **Givner LB**, Yogev R, Kim KS, Kaplan SL. Clinical and pleural fluid parameters in children with complicated pneumococcal pneumonia. Presented to the Society for Pediatric Research, Boston, Massachusetts, May 13, 2000.
43. Schutze GE and the US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Wake Forest). Streptococcus pneumoniae infections in transplant patients. Presented to the Society for Pediatric Research, Boston, Massachusetts, May 13, 2000.
44. **Givner LB** and the US Pediatric Multicenter Pneumococcal Surveillance Group. Pneumococcal facial cellulitis. Presented to the Society for Pediatric Research, Boston, Massachusetts, May 13, 2000.
45. Kaplan SL, Barson WJ, Wald ER, Schutze GE, Bradley JS, Tan TQ, Kim KS, **Givner LB**, Yogev R, Mason EO Jr. Outcome of invasive non-CNS infections due to S. pneumoniae isolates non-susceptible to ceftriaxone treated with  $\beta$ -lactam antibiotics. Presented to the Society for Pediatric Research, Boston, Massachusetts, May 14, 2000.
46. Kaplan SL, Barson WJ, Wald ER, Schutze GE, Bradley JS, Tan TQ, Kim KS, **Givner LB**, Yogev R, Mason EO. Six year surveillance of invasive pneumococcal infections in children: 1993-99. Presented to the Infectious Diseases Society of America, New Orleans, Louisiana, September 7-10, 2000.
47. Karchmer TB, Adkins C, Gaither B, Block S, **Givner L**, Sherertz R. Use of surveillance cultures to control a methicillin-resistant *Staphylococcus aureus* outbreak in a neonatal intensive care unit. Presented to the Society for Healthcare Epidemiology of America, Toronto, Canada, April 1-3, 2001.
48. Tan TQ, Mason EO, Wald ER, Barson WJ, Schutze GE, Yogev R, **Givner LB**, Bradley JS, Kim KS, Kaplan SL. Clinical characteristics of children with complicated pneumococcal pneumonia caused by serotype 1. Presented to the Society for Pediatric Research, Baltimore, Maryland, April 29, 2001.
49. Schutze GE and the US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Wake Forest). Invasive pneumococcal infections in children without a spleen. Presented to the Society for Pediatric Research, Baltimore, Maryland, April 29, 2001.
50. Nagaraj SK and the US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Wake Forest). Invasive Streptococcus pneumoniae infections in childhood nephrotic syndrome. Presented to the Society for Pediatric Research, Baltimore, Maryland, May 5, 2002.
51. Hoffman J and the US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Wake Forest). Streptococcus pneumoniae infections in neonates. Presented to the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2002.
52. Kaplan SL and the US Pediatric Multicenter Pneumococcal Surveillance Group (**Givner LB**, Principal Investigator at Wake Forest). Decline in invasive Streptococcus pneumoniae infections in eight

children's hospitals. Presented to the Society for Pediatric Research, Seattle, Washington, May 3-6, 2003.

**Miscellaneous:**

1. **Givner LB.** Infections caused by Salmonella cholera-suis. J Pediatr 1981; 99:502. (Letter)
2. **Givner LB.** Chlamydia trachomatis infections in infants. Pediatric Basics 1988;50:9-12.
3. Abramson JS, **Givner LB.** Tetracycline for Rocky Mountain spotted fever. Pediatrics 1991; 87:125. (Letter)
4. **Givner LB.** Arcanobacterium haemolyticum sepsis and Epstein-Barr virus infection. Pediatr Infect Dis J 1992; 11:417-418. (Letter)
5. Abramson JS, **Givner LB**, Woods CR Jr. Bismuth in infants with watery diarrhea. N Engl J Med 1993; 329:1742-1743. (Letter)